Portfolio Analysis in London.

A patent portfolio analysis London teams can act on has to start from a fact that changed the whole map in 2020: the United Kingdom sits outside the Unitary Patent and the Unified Patent Court. The UK withdrew its ratification of the UPC Agreement on 20 July 2020, so a European patent covering the UK is validated and renewed nationally through the Intellectual Property Office (UKIPO), entirely separate from any unitary right on the continent. For an in-house IP team or an R&D leader in London – Europe’s largest finance, fintech and life-sciences cluster – that split turns routine estate management into a strategic decision: where to file, what to validate, what to opt out, and what to let lapse. This page sets out how we analyse the landscape, gaps, strength and value of a London-anchored portfolio against that reality.

Patent portfolio analysis London: why it starts at the post-Brexit UPC gap

The single biggest structural fact for a London portfolio is that the UK is a European Patent Convention state but is not part of the Unitary Patent package or the Unified Patent Court. When the UK withdrew its UPC ratification on 20 July 2020, it took itself out of a system where one right and one court could cover most of the EU. A European patent that is meant to bite in Britain must therefore be validated as a national UK patent and maintained at the UKIPO on its own renewal schedule.

That creates a two-track estate for almost every London company of scale. On the continent, a granted European patent can be taken with unitary effect across the participating states, or validated country by country, and disputes run through the UPC unless the proprietor has opted out. In the UK, none of that applies: coverage comes only from a validated national patent, and enforcement runs through the UK courts. A unitary patent never reaches the UK, full stop.

So the analysis a London IP team actually needs answers a sequence of questions the pre-Brexit playbook never asked. Which continental members of a family should carry unitary effect and which should stay classical and opted out? Where does the UK national validation sit against that, and is the UK claim scope still aligned with the EP grant? Which families justify the separate UK renewal spend at all? A portfolio review that ignores the UPC boundary will systematically misprice the British half of the estate.

We map every family onto that split first, then layer landscape, gap and strength scoring on top, so the board sees a UK position and a UPC-territory position as two connected but distinct assets rather than one blurred European line item.

London’s finance, fintech, life-sciences and AI base shapes the estate

London is one of the world’s two leading financial centres, and its patent profile reflects that far more than a typical national capital. The filing base clusters around a handful of sectors, and each one stresses a portfolio differently.

• Finance and fintech — payments, trading infrastructure, risk engines and open-banking platforms clustered in the City and Canary Wharf. Much of it is software-implemented, so the analysis has to test whether claims survive the excluded-subject-matter rules for computer programs and business methods under the Patents Act 1977.
• Life sciences and pharma — the Francis Crick Institute, the King’s Cross knowledge quarter and the wider golden triangle with Oxford and Cambridge. Here supplementary protection certificates, second-medical-use claims and family depth in the UK, EP and US drive most of the portfolio value.
• Artificial intelligence and deep tech — DeepMind and a dense start-up scene generating machine-learning and data-processing inventions where inventorship and subject-matter eligibility are both live issues.
• Creative, media and telecoms — codecs, streaming and connectivity work that frequently touches standard-essential patents and FRAND licensing.

For an in-house team, this mix means one review methodology never fits the whole estate. A fintech family is judged on claim breadth and freedom to operate; a life-sciences family on term extension and blocking strength; a telecoms family on essentiality and licensing income. Our strength scoring is weighted per sector rather than applied as a single template, because a London portfolio is rarely built on one technology alone.

FRAND and SEP value: the Unwired Planet legacy in a London estate

If any of the families in a portfolio touch a technical standard – cellular, video, connectivity or audio – their value is shaped by a landmark London judgment. In Unwired Planet v Huawei [2020] UKSC 37, decided on 26 August 2020, the UK Supreme Court held that the English courts have jurisdiction to determine the terms of a global FRAND licence for a portfolio of standard-essential patents, and to grant an injunction where an implementer refuses to take one.

That decision made London one of the most important standard-essential-patent forums in the world. A single UK-litigated patent can become the lever that sets a worldwide royalty rate across an entire portfolio, and the court confirmed that the non-discrimination limb of FRAND is “general” rather than “hard-edged” – a rate reflecting the value of the SEPs licensed does not stop being FRAND just because an earlier licensee got better terms.

For portfolio analysis this cuts two ways. If a London company owns declared-essential patents, the estate may carry global licensing value that a naive family-count valuation completely misses; the questions become essentiality, standard version and comparable licences. If instead a company implements standards, the same case is a liability lens – a rival’s UK SEP can force a global negotiation, so the portfolio has to be reviewed for defensive depth and cross-licensing weight.

We flag every potentially standard-essential family in a review, assess declared essentiality against the relevant standard, and score the portfolio for both offensive licensing upside and defensive exposure in the London FRAND forum.

AI-invention portfolios after the DABUS ruling

London’s AI and deep-tech density makes one recent decision unavoidable in any modern portfolio review. In Thaler v Comptroller-General [2023] UKSC 49, handed down in December 2023, the UK Supreme Court unanimously held that an inventor under section 7 of the Patents Act 1977 must be a natural person – a human being – and that an AI system such as Dr Thaler’s DABUS cannot be named as the inventor.

The practical consequence is direct: a UK application that fails to identify a human inventor is taken to be withdrawn. For a company generating inventions with heavy machine-learning involvement, this is not an abstract debate. It is a filing-hygiene issue that runs through the whole estate. Every family has to be able to name the human beings who devised the invention and to explain their contribution, even where an AI tool did much of the computational work.

In a portfolio audit we treat AI-assisted families as a distinct risk category. We check that inventorship records identify real people, that assignment chains from those individuals are complete, and that the contribution narrative would survive scrutiny. A gap here does not just weaken one patent – it can put a cluster of the company’s most commercially important AI filings at risk at once, which is exactly the kind of concentrated exposure a portfolio review exists to surface.

Renewal-fee strategy and pruning across a UK and EP estate

Because the UK maintains its patents separately from any continental right, renewal-fee planning is a core portfolio-management lever for London teams rather than an administrative afterthought. UKIPO renewal fees fall due annually from the end of the fifth year after filing and escalate steeply across the twenty-year term – from a modest fee in the early years to several times that by year twenty – a schedule deliberately designed to make proprietors reassess whether an ageing patent still earns its keep.

The UKIPO renewal window opens three months before the anniversary and stays open one month after without penalty; miss it and a six-month grace period applies with a monthly surcharge on top of the standard fee. Fees rose again on 1 April 2026, so the exact figures should always be confirmed against the current UKIPO schedule before a budget is set.

Run that across a two-track estate and the numbers compound. A single invention may be paying UK national renewals, unitary or per-country renewals on the continent, and US maintenance fees simultaneously. A portfolio analysis models that combined spend family by family and sets it against each family’s strength score and commercial relevance, so a finance team can see where renewal money is defending revenue and where it is defending nothing.

Pruning is the output. We recommend which families to maintain in full, which to trim geographically – keeping the UK and core EP states while dropping marginal territories – and which to allow to lapse, turning a recurring cost line into freed budget for new filings that matter more.

The enforcement-cost lens: IPEC and the Patents Court

A portfolio is only as valuable as it is enforceable, and London gives IP owners two very different venues – a fact that belongs in a strength analysis, not just a litigation plan. The Intellectual Property Enterprise Court (IPEC) is built for smaller and mid-sized disputes: damages are capped at £500,000 and recoverable costs at roughly £60,000 for a liability trial (raised from £50,000 in October 2022), with trials generally limited to two days.

The Patents Court, part of the Business and Property Courts of the High Court, handles the heavyweight cases – complex, high-value patents with expert evidence and no costs cap. Which court a family would realistically be enforced in is a genuine signal of its commercial weight, and it changes how a rational owner should invest in it.

We fold this into portfolio triage. Families whose likely disputes are low-value and clear-cut can be defended affordably in IPEC, which raises the sensible ceiling on renewal and prosecution spend for them. Families that would only ever be fought in the Patents Court – the crown-jewel assets – justify deeper investment in claim quality, family depth and evidential support. Reading the estate through the venue that would actually enforce it turns an abstract strength score into a budget a board can defend.

How PerspireIP runs the review for London IP teams and R&D leaders

Our engagement is built for in-house IP counsel, heads of legal and R&D leaders who need a defensible view of an estate – whether for annual planning, an M&A or venture-capital due-diligence exercise, or a licensing push. We work from your patent register, prosecution files and product roadmap and deliver a structured analysis rather than a raw export.

• Landscape analysis — where your families sit against competitors and the wider technical field, with white-space and crowding mapped per technology area
• Gap analysis — the products, features and jurisdictions your current claims do not cover, including the UK-versus-UPC-territory split
• Strength scoring — claim breadth, family depth, remaining term, litigation history and, where relevant, standard-essentiality, weighted by sector
• Valuation and cost modelling — combined UK, EP and US renewal spend set against each family’s commercial relevance, with prune, maintain and reinforce recommendations
• Risk flags — AI-inventorship exposure after Thaler, FRAND exposure after Unwired Planet, and assignment or inventorship gaps that could unwind a family

The deliverable is a board-ready report: a ranked family list, a landscape and gap picture, a strength-versus-cost matrix, and a prioritised action plan. Because we are search and analysis specialists rather than a filing firm, the recommendations are independent – we are not incentivised to keep any particular family alive. That independence is why London teams use us for due-diligence work where a second, unconflicted opinion carries weight with investors and acquirers.

Whether you are pressure-testing an estate before a funding round, rationalising renewal spend, or building a licensing case around standard-essential assets, we turn a scattered patent register into a strategy you can act on.

IP Landscape & Resources in London

Key intellectual-property authorities and venues relevant to London:

• UK Intellectual Property Office (UKIPO) — the official body that grants UK national patents, records validations of European patents in the UK, and collects the annual renewal fees that drive UK portfolio-maintenance decisions
• The Patents Court (Business and Property Courts of the High Court) — the High Court forum for complex, high-value UK patent disputes with no costs cap – the venue that defines the top tier of an estate's enforceable value
• Intellectual Property Enterprise Court (IPEC) — the cost-capped court for smaller and mid-sized IP claims, with damages capped at GBP 500,000 and recoverable costs around GBP 60,000 for a liability trial
• World Intellectual Property Organization (WIPO) — administers the PCT and PATENTSCOPE and publishes global filing statistics used to benchmark a portfolio's international footprint and landscape position

Book a Patent Portfolio Review for Your London IP Team

Explore related PerspireIP services: Patent Portfolio Analysis services · IP services in the United Kingdom · patent invalidation in London · prior art and litigation search in London · patent infringement analysis in London · patent monetization in London.

Frequently Asked Questions